Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75
Sponsor: Christopher Sweeney, MBBS
Listed as NCT00234494, this PHASE2 trial focuses on Bladder Cancer and remains completed. Sponsored by Christopher Sweeney, MBBS, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Christopher Sweeney, MBBS
- Eli Lilly and Company
- Genentech, Inc.
- Hoosier Cancer Research Network
- Walther Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .